Royal Bank of Canada’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Royal Bank of Canada’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-100	Closed	-$3K	–	6472
2014 Q1	$3K	Buy	+100	New	+$3.42K	﹤0.01%	5708

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Royal Bank of Canada's CTIC Position: Q2 2023 in Review

Royal Bank of Canada sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 6,669 shares — an estimated $28K sold.

Royal Bank of Canada first reported a position in CTIC in Q3 2013 and held it in 29 quarters. The position peaked at $101K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Royal Bank of Canada reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Royal Bank of Canada sold 6,669 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $28K.
Royal Bank of Canada first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 29 quarters.
Royal Bank of Canada's CTI BioPharma Corp. (DE) Common Stock position peaked at $101K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.